Studies have shown that reduced KRT18 expression enhances the susceptibility of cervical cancer cells to cytokine-induced cell death, inhibits cell migration (79), and enhances the sensitivity to paclitaxel in LC (75). This evidence concerns the gene KRT18 and cervical carcinoma.